Labcorp (LH)
(Real Time Quote from BATS)
$215.15 USD
+0.08 (0.04%)
Updated Oct 4, 2024 12:52 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Company Summary
Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.
In May 2024, Labcorp completed its new public holding company recognition structure.The new parent company, Labcorp Holdings Inc., replaced Laboratory Corporation of America Holdings (LCAH) as the publicly traded entity. Subsequently, LCAH became ...
Company Summary
Headquartered in Burlington, NC, Labcorp Holdings, Inc. or Labcorp, is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.
In May 2024, Labcorp completed its new public holding company recognition structure.The new parent company, Labcorp Holdings Inc., replaced Laboratory Corporation of America Holdings (LCAH) as the publicly traded entity. Subsequently, LCAH became the wholly owned subsidiary of Labcorp Holdings Inc.
Post the spin-off of Fortrea on Jun 30, 2023, Labcorp reports its laboratory service business under two segments —
Diagnostics Laboratories (Dx) comprised 77% of the company’s revenues in 2023, up 2.2% from 2022. The segment offers a comprehensive menu of frequently requested core testing and specialty testing through an integrated network of primary and specialty laboratories across the United States and Canada.
Biopharma Laboratory Services (“BLS”) (23% of net sales, up 2.8%): This includes the remaining operations of the previously reported Drug Development segment. Biopharma laboratory services consist of two businesses — the Central Laboratories business, which represents about 70% of the segment’s revenues, and Early Development Research Laboratories, smaller in proportion but a leader in the market.
General Information
Labcorp
358 South Main Street
BURLINGTON, NC 27215
Phone: 336-229-1127
Fax: 336-513-4510
Email: investor@labcorp.com
Industry | Medical - Dental Supplies |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Earnings Date | 10/24/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 3.50 |
Current Year EPS Consensus Estimate | 14.56 |
Estimated Long-Term EPS Growth Rate | 8.90 |
Earnings Date | 10/24/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 215.07 |
52 Week High | 238.47 |
52 Week Low | 191.97 |
Beta | 1.05 |
20 Day Moving Average | 544,589.75 |
Target Price Consensus | 254.00 |
4 Week | -5.40 |
12 Week | 4.28 |
YTD | -5.38 |
4 Week | -8.66 |
12 Week | 2.17 |
YTD | -20.82 |
Shares Outstanding (millions) | 83.96 |
Market Capitalization (millions) | 18,057.98 |
Short Ratio | NA |
Last Split Date | 5/13/2002 |
Dividend Yield | 1.34% |
Annual Dividend | $2.88 |
Payout Ratio | 0.20 |
Change in Payout Ratio | 0.12 |
Last Dividend Payout / Amount | 8/29/2024 / $0.72 |
Fundamental Ratios
P/E (F1) | 14.77 |
Trailing 12 Months | 15.04 |
PEG Ratio | 1.66 |
vs. Previous Year | 15.20% |
vs. Previous Quarter | 7.07% |
vs. Previous Year | 6.17% |
vs. Previous Quarter | 1.39% |
Price/Book | 2.26 |
Price/Cash Flow | 10.58 |
Price / Sales | 1.45 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 15.39 |
3/31/24 | 14.68 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 7.30 |
3/31/24 | 7.03 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.88 |
3/31/24 | 0.88 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.77 |
3/31/24 | 0.76 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 9.77 |
3/31/24 | 9.69 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 3.60 |
3/31/24 | 3.52 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 5.26 |
3/31/24 | 4.83 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 94.97 |
3/31/24 | 94.43 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 19.41 |
3/31/24 | 18.73 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.39 |
3/31/24 | 0.39 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 28.17 |
3/31/24 | 28.29 |